The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial
Abstract
BACKGROUND: ITALUNG is contributing to the European evaluation of low-dose CT (LDCT) screening for lung cancer (LC). METHODS: Eligible subjects aged 55-69 years, smokers or ex-smokers (at least 20 pack-years in the last 10 years), were randomised to receive an annual invitation for LDCT screening for 4 years (active group) or to usual care (control group). All participants were followed up for vital status and cause of death (at the end of 2014) and LC incidence (at the end of 2013). Pathological and clinical information was collected from the Tuscan Cancer Registry data. RESULTS: 1613 subjects were randomly assigned to the active group and 1593 to the control group. At the end of the follow-up period 67 LC cases were diagnosed in the active group and 71 in the control group (rate ratio (RR)=0.93; 95% CI 0.67 to 1.30). A greater proportion of stage I LC was observed in the active group (36% vs 11%, p<0.001). Non-significant reductions of 17% (RR=0.83; 95% CI 0.67 to 1.03) for overall mortality and 30% (RR=0.70; 95% CI 0.47 to 1.03) for LC-specific mortality were estimated. CONCLUSIONS: Despite the lack of statistical significance, the ITALUNG trial outcomes suggest that LDCT screening could reduce LC and overall mortality. Moreover, the comparison of the number of LC cases diagnosed in the two groups does not show overdiagnosis after an adequate follow-up period. A pooled analysis of all European screening trials is advocated to assess the benefit-to-harm ratio of LDCT screening and its implementation in public health settings. TRIAL REGISTRATION NUMBER: Results, NCT02777996.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
International Classification of Diseases for Oncology
National Cancer Institute (2020) · Definitions · doi:10.32388/1bjeus · Cited by 3,805
Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2014) · Annals of Internal Medicine · doi:10.7326/m13-2771 · Cited by 2,632
International Classification of Diseases for Oncology
Trott, P. A. (1977) · Journal of Clinical Pathology · doi:10.1136/jcp.30.8.782-c · Cited by 1,676
Price, M. J., Ades, A., Soldan, K., Welton, N. J., Macleod, J., Simms, I., DeAngelis, D., Turner, K. M., & Horner, P. J. (2016) · Health Technology Assessment · doi:10.3310/hta20220 · Cited by 494
van Iersel, C. A., de Koning, H. J., Draisma, G., Mali, W. P. T. M., Scholten, E. T., Nackaerts, K., Prokop, M., Habbema, J. D. F., Oudkerk, M., & van Klaveren, R. J. (2007) · International Journal of Cancer · doi:10.1002/ijc.22134 · Cited by 494
Pedersen, J. H., Ashraf, H., Dirksen, A., Bach, K., Hansen, H., Toennesen, P., Thorsen, H., Brodersen, J., Skov, B. G., Døssing, M., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a0d98f · Cited by 434
Pastorino, U., Rossi, M., Rosato, V., Marchianò, A., Sverzellati, N., Morosi, C., Fabbri, A., Galeone, C., Negri, E., Sozzi, G., et al. (2012) · European Journal of Cancer Prevention · doi:10.1097/cej.0b013e328351e1b6 · Cited by 414
Saghir, Z., Dirksen, A., Ashraf, H., Bach, K. S., Brodersen, J., Clementsen, P. F., Døssing, M., Hansen, H., Kofoed, K. F., Larsen, K. R., et al. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-200736 · Cited by 390
Infante, M., Cavuto, S., Lutman, F. R., Passera, E., Chiarenza, M., Chiesa, G., Brambilla, G., Angeli, E., Aranzulla, G., Chiti, A., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201408-1475oc · Cited by 365
Cited by
The global burden of lung cancer: current status and future trends
Leiter, A., Veluswamy, R. R., & Wisnivesky, J. P. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00798-3 · Cited by 1,477
Progress and prospects of early detection in lung cancer
Blandin Knight, S., Crosbie, P. A., Balata, H., Chudziak, J., Hussell, T., & Dive, C. (2017) · Open Biology · doi:10.1098/rsob.170070 · Cited by 935
Jonas, D. E., Reuland, D. S., Reddy, S. M., Nagle, M., Clark, S. D., Weber, R. P., Enyioha, C., Malo, T. L., Brenner, A. T., Armstrong, C., et al. (2021) · JAMA · doi:10.1001/jama.2021.0377 · Cited by 633
European position statement on lung cancer screening
Oudkerk, M., Devaraj, A., Vliegenthart, R., Henzler, T., Prosch, H., Heussel, C. P., Bastarrika, G., Sverzellati, N., Mascalchi, M., Delorme, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30861-6 · Cited by 587
Self-citationHendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
Metadata
- Authors
- Paci, E., Puliti, D., Lopes Pegna, A., Carrozzi, L., Picozzi, G., Falaschi, F., Pistelli, F., Aquilini, F., Ocello, C., Zappa, M., Carozzi, F. M., & Mascalchi, M.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2017-04-04
- Volume
- 72
- Issue
- 9
- Pages
- 825-831
- ISSN
- 0040-6376 (ISSN-L)
- 1468-3296
- OpenAlex
- W2604338567
- Cited by
- 311
- References
- 22
- FWCI
- 19.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. https://app.cochat.ai/papers/10.1136/thoraxjnl-2016-209825
- The paper
- Paci, E., Puliti, D., Lopes Pegna, A., Carrozzi, L., Picozzi, G., Falaschi, F., Pistelli, F., Aquilini, F., Ocello, C., Zappa, M., Carozzi, F. M., & Mascalchi, M. (2017). Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax. https://doi.org/10.1136/thoraxjnl-2016-209825
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.